AI Article Synopsis
- In 2019, oncology experienced significant advancements due to specialized medicine and personalized treatments.
- Key treatments gained importance and expanded their uses, while new innovative therapies in research raised hopes for future developments.
- Biomarkers like PD-L1, MSI, TMB, BRCA1/2 mutations, and HRD improved the selection and customization of available cancer treatments.
Article Abstract
Driven by highly specialized medicine, research and the quest for personalization of treatments, oncology witnessed substantial advances in 2019. This year numerous treatments have consolidated their importance and broadened their indications. Multiple innovative treatments, currently under study, brought hope for future advances, while biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), BRCA1/2 gene mutations, and homologous recombination deficiency (HRD) allowed better selection and customization of available treatments. This article provides an overview of this year's advances in oncology.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!